Search

everythinglearnresearchcommunity

for

Search:↓

The user has been experiencing diffuse hair thinning despite using finasteride, minoxidil, dermarolling, clobetasol cream, and PRP sessions. They seek advice on additional treatments and are advised to check vitamin D, iron, and thyroid levels.

21-year-old female experiencing hair loss and visible scalp seeks advice on PRP effectiveness. Currently taking spironolactone and krimson for high androgens, unsure if PRP can be done with these medications.

PP405 shows promise as a hair loss treatment, with 31% experiencing increased hair density in a short trial. It may complement treatments like finasteride and minoxidil, but long-term effectiveness and safety need confirmation.

A potential new hair loss treatment, HMI-115, and the possibility of discontinuing finasteride in favor of it. The conversation also includes discussion about other benefits of using finasteride.

The conversation discusses hair loss treatments, with the main focus on using Fluridil and considering switching to Pyrilutamide. Other treatments mentioned include minoxidil, topical finasteride, nizoral shampoo, and saw palmetto supplements, with advice to stick with Fluridil for at least six months before considering alternatives.

The conversation discusses the safety study of PP405, emphasizing that early trials focus on safety rather than efficacy, and that any efficacy data from such a short study should be viewed skeptically. It also highlights that the information released is primarily for securing funding, and that meaningful efficacy results are expected in later phases.

A peptide-based hair loss treatment, PP405, reportedly increased hair density by 62% in 90 days, but these claims are unverified and met with skepticism. Users compared PP405 to Minoxidil and Finasteride, expressing doubts about its effectiveness without more evidence.

A user's two month update on their hair loss journey and the treatments they are trying, which include exosome injections, minoxidil, finasteride, and RU58841.

The user is using testosterone and finasteride to prevent hair loss and is considering adding Primobolan or Masteron, which are DHT-derivatives. They are seeking advice on their genetic risk for male pattern baldness and whether they can safely use these compounds without significant hair loss.

The conversation introduces a specialized chatbot for ChatGPT Plus users that provides advice on hair loss treatments, drawing from research and community insights. It mentions treatments like RU58841, the "big 4" (likely minoxidil, finasteride, ketoconazole, and tretinoin), dutasteride mesotherapy, topical melatonin, microneedling, and rapamycin.

Recruitment for a verteporfin trial and a separate hair cloning trial using verteporfin and other methods is underway, with locations in Jordan, NYC, Beverly Hills, and Memphis. Dr. Bloxham is conducting the hair cloning trial, and interested participants are encouraged to contact him directly.

IGFBP‐rP1 shows potential for treating androgenic alopecia by influencing hair cycle transitions. Increasing IGF-1 levels may have similar effects to Minoxidil and 5-AR inhibitors in reducing hair loss.

PP405 is being discussed as a potential treatment for hair loss, with uncertainty about its effectiveness compared to existing treatments like finasteride, dutasteride, and minoxidil. There is cautious optimism, but its impact on hair transplants remains unclear.

The user is unsatisfied with their hair transplant and is considering another transplant, PRP, exosomes, or stem cells. They currently use topical minoxidil, dutasteride, and tretinoin.

A 33-year-old male experienced initial hair improvement with exosomes, PRP, Regenera, oral minoxidil (2.5mg), and finasteride (1mg), but his condition worsened after stopping treatments. He is considering a hair transplant and seeks advice on its viability.

The user is using oral finasteride, minoxidil, and KX-826 for hair regrowth, noticing small improvements. They plan to add ketoconazole shampoo and consider a hair transplant with verteporfin after a year of treatment.

The conversation discusses hair loss treatments, specifically Verteporfin. Users also mention Minoxidil, finasteride, and RU58841.

PP405 is a safer alternative to JXL069 for hair loss treatment because it penetrates the skin effectively and degrades in the blood, avoiding systemic toxicity. JXL069, when forced into the body, can cause dangerous side effects like lactic acidosis due to its inability to degrade safely.

The conversation discusses the differences between KB solution and PG + Ethanol solution for RU58841 in treating hair loss. It compares the effectiveness and properties of these two solutions.

The user has been using finasteride, ketoconazole shampoo, oral minoxidil, and minoxidil foam for hair loss but feels their hair is not as thick as desired. They have stopped using RU58841 due to lack of results and are concerned about hair miniaturization despite these treatments.

The conversation discusses new hair loss treatments like stem cell therapy, exosome treatments, and DHI, with mentions of GT20029, Amp303, and Plated PRP Serum as promising options. It also notes the use of dutasteride, topical finasteride, and minoxidil, but the focus is on non-hormonal innovations.

The conversation discusses a 4-month hair regrowth protocol that includes finasteride (1.25mg), RU58841, dermarolling, ketoconazole, minoxidil, peppermint oil, and fatty acids/oils. Progress pictures are shared to show the results of these treatments.

Concerns about the potential systemic effects and safety of PP405 for hair loss, with discussions on its comparison to existing treatments like finasteride and minoxidil. Users express skepticism about untested research chemicals and emphasize the importance of clinical trials to ensure safety and efficacy.

The conversation is about a person using dutasteride and minoxidil for hair loss, considering adding RU58841 and PP405 for more density. They are seeking advice on using these treatments and exploring other options like GT20029.

The conversation discusses the delay in the PP405 Phase 2 study results, now expected by the end of 2025, and skepticism about research practices. There is also mention of optimism for Amplifica's AMP303 and a topical treatment in early testing.

A new hair loss treatment, PP405, is moving from phase 2A to 2B in clinical trials, sparking discussions about its potential to regrow dormant hairs and its impact on existing treatments like Minoxidil and finasteride. Some users express skepticism, while others are hopeful about its future effectiveness.

The user started using finasteride, minoxidil, and biotin for hair loss and believes they are a hyper responder, noticing significant changes in hair thickness. They regret not starting earlier and mention using oral minoxidil.

PP405 is a potential hair loss treatment that may activate dormant hair follicles, but there are concerns about its effectiveness, cost, and side effects. Users discuss treatments like minoxidil, finasteride, and RU58841, expressing skepticism about PP405's long-term success and accessibility.

Verteporfin treatment shows promise for hair regeneration and reducing scar tissue in hair transplants. Some users plan to try verteporfin with hair transplants, and it may also be combined with PRP in future experiments.

TDM-105795 showed promising hair growth results, with higher efficacy than placebo and minimal side effects. It activates dormant hair follicle stem cells and may maintain gains without immediate loss, unlike minoxidil.